Eylea, Avastin Both Get A Boost From NIH Comparative Study In DME
This article was originally published in The Pink Sheet Daily
The first head-to-head comparison of Eylea, Avastin and Lucentis in diabetic macular edema shows a superior benefit for Eylea in patients with more advanced vision loss and that Avastin is as effective as the other two drugs in other patients.
You may also be interested in...
The firm got off to a solid start in 2016, which should see its biggest launches in years, but its core strength remains executing long-term management of its key franchises.
Regeneron and Bayer look to build on their past success collaborating in ophthalmology by partnering to develop an Eylea successor. Sun Pharma builds its portfolio with 13 products from Novartis.
Latest ophthalmologic collaboration between the partners seeks to create an Eylea successor by combining aflibercept with an Ang2 antibody.